Steven R. Hays MD
Critical Care Medicine, Cystic Fibrosis, Interstitial Lung Diseases, Lung Transplantation Medicine
Professor of Medicine, Medical Director Lung Transplantation, UCSF School of Medicine
Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2961
Fax+1 415-353-2568
Dr. Hays is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Hays is a pulmonologist in San Francisco, CA and is affiliated with UCSF Medical Center. He received his medical degree from University of Kansas School of Medicine and underwent his specialty training at UCSF and Stanford Medical Center. He has been in practice for 22 years and specializes in lung transplantation medicine, cystic fibrosis, interstitial lung diseases, and alpha-1 anti-trypsin deficiency.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1999 - 2003
University of Kansas School of MedicineChief Residency, Internal Medicine, 1998 - 1999- University of Kansas School of MedicineResidency, Internal Medicine, 1995 - 1998
- University of Kansas School of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 1999 - 2027
OR State Medical License 2015 - 2025
American Board of Internal Medicine Critical Care Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Start of enrollment: 2013 Jul 01
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) Start of enrollment: 2019 Mar 26
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Start of enrollment: 2019 Mar 26
Publications & Presentations
PubMed
- GDF15 is a putative biomarker for distinguishing pulmonary veno-occlusive disease and pulmonary arterial hypertension.Amit Prabhakar, Eckart Mdd De Bie, Jacqueline T DesJardin, Prajakta Ghatpande, Stefan Gräf
The Journal of Clinical Investigation. 2025-11-20 - CD26/DPP-IV inhibitors and associations with chronic lung allograft dysfunction in a multicenter cohort.Alexander R Graham, Maria V Grau-Sepulveda, Erika J Bush Buckley, Daniel F Dilling, Albert Faro
The Journal of Heart and Lung Transplantation. 2025-09-01 - Probable reactivation from latency of multidrug-resistant cytomegalovirus in a lung transplant recipient: A case report.Julia A Wagner, Rama Yakubu, Adrian M Whelan, Steven R Hays, Helen C Stankiewicz Karita
American Journal of Transplantation. 2025-08-23
Journal Articles
- Genotypes Associated with Tacrolimus Pharmacokinetics Impact Clinical Outcomes in Lung Transplant RecipientsSteven R. Hays, Hilary Faust, Jonathan P. Singer, Clinical Transplantation
Press Mentions
Episode 31: June 2023June 7th, 2023- How Digital Health Is Making UCSF's Lung Transplant Program More AccessibleJune 11th, 2021
Grant Support
- Mechanisms Of Gland Proliferation In COPDNational Heart, Lung, And Blood Institute2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
